Table 2 Clinical features associated with positive results^a.

All gene univariate analysis (n = 1812)
	All gene carriers (n = 262)	All gene negative (n = 1550)	OR (95% CI)	p value
Percentage	14.46%	85.54%
Age at Dx (IQR)	59 (53.75, 65)	60 (54, 66)	0.99 (0.98, 1.01)	0.32
Personal history of other cancer
Yes	126	632	1.35 (1.03, 1.75)	2.67E-02
No	136	918
Family history of cancer FDR only^b
Yes	222	1295	1.09 (0.77, 1.59)	0.631
No	40	255
Family history of PC FDR only
Yes	103	582	1.08 (0.82, 1.41)	0.59
No	159	968
Family history of PC^c
Yes	137	780	1.08 (0.83, 1.41)	0.56
No	125	770
Met Hopkins FPC criteria
Yes	46	317	0.92 (0.65, 1.28)	0.61
No	229	1446
>1 relative with breast, ovarian or pancreatic cancer^c
Yes	114	535	1.46 (1.12, 1.9)	5.14E-03
No	148	1015
>1 relative with Lynch-related cancer^c
Yes	97	475	1.33 (1.01, 1.74)	0.04
No	165	1075
HBOC criteria
Yes	67	313	1.36 (1, 1.83)	1.94E-05
No	195	1237
Lynch criteria
Yes	89	337	1.85 (1.39, 2.45)	1.94E-05
No	173	1213
Metastatic
Yes	33	164	1.45 (0.57, 4.45)	0.47
No	5	36
Missing	224	1350	1.19 (0.51, 3.51)	0.71
Gleason score
<7	17	145
≥7	106	649	1.39 (0.83, 2.47)	0.23
Missing	139	756	1.57 (0.94, 2.76)	0.099

CI confidence interval, Dx diagnosis, FDR first-degree relative, FPC familial prostate cancer, HBOC hereditary breast and ovarian cancer, OR odds ratio, PC prostate cancer.
^aClinical variables as reported on test requisition forms.
^bNonmelanoma skin cancers and unspecified cancers are excluded.
^cIncludes first, second, and third-degree relatives.
Statistically significant values are in bold.

Quick links

Search